CPT2 and squamous cell lung carcinoma: In order to learn more about the connection between CPT2 and immunotherapy, we discovered that patients with lung squamous cell carcinoma who received anti-PDL1 and anti-CTLA-4 treatment had higher survival rates when CPT2 was highly expressed (Figure 5C).